Vivos Therapeutics, Inc. v. Ortho-Tain, Inc.

CourtDistrict Court, D. Colorado
DecidedFebruary 14, 2024
Docket1:20-cv-01634
StatusUnknown

This text of Vivos Therapeutics, Inc. v. Ortho-Tain, Inc. (Vivos Therapeutics, Inc. v. Ortho-Tain, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vivos Therapeutics, Inc. v. Ortho-Tain, Inc., (D. Colo. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Judge William J. Martínez

Civil Action No. 20-cv-1634-WJM-JPO

VIVOS THERAPEUTICS, INC.,

Plaintiff,

v.

ORTHO-TAIN, INC.,

Defendant.

ORDER DENYING DEFENDANT’S MOTION TO DISMISS1

This matter is before the Court on Defendant Ortho-Tain, Inc.’s (“Ortho-Tain”) Motion to Dismiss Plaintiff Vivos Therapeutics, Inc.’s (“Vivos”) First Amended Complaint (“Motion”) (ECF No. 45). For the following reasons, the Motion is denied. I. BACKGROUND The following facts are taken from Vivos’s Amended Complaint (“AC”) and are assumed true for the purpose of resolving the Motion. See Ridge at Red Hawk, L.L.C. v. Schneider, 493 F.3d 1174, 1177 (10th Cir. 2007).

1 The Court issued an earlier version of this Order on September 3, 2021. (ECF No. 58.) Ortho- Tain appealed that Order. (ECF No. 59.) The Tenth Circuit held it had jurisdiction to consider Ortho-Tain’s appeal with respect to its claim of the litigation privilege on an interlocutory basis. (ECF No. 71 at 4.) However, the Tenth Circuit declined to exercise pendant jurisdiction to review the Court’s other non-final rulings. (Id. at 9.)

On the merits, the Tenth Circuit reversed and remanded the Court’s ruling “[t]o the extent the denial of immunity turned on a question of law” and dismissed the appeal “[t]o the extent the denial of immunity turned on the factual inadequacy of the record . . . .” (Id. at 10– 11.) The Court now reissues its Order with an amended analysis of Ortho-Tain’s claim of the litigation privilege. No other aspect of this Order has been altered from the one issued on September 3, 2021. This action arises out of Ortho-Tain’s alleged interference with Vivos’s relationships with its clients. (ECF No. 40.) Vivos and Ortho-Tain are both manufacturers of dental equipment which market their products to dentists and dental offices. (Id. ¶¶ 1–3.) In the Spring of 2020, Ortho-Tain’s Chief Executive Officer (“CEO”) contacted

Vivos’s affiliate, Benco. (Id. ¶¶ 21–24.) Ortho-Tain stated that Benco was displaying Ortho-Tain marketing materials in a Vivos-sponsored course in violation of the Lanham Act, 15 U.S.C. §§ 1051, et seq. (Id. ¶¶ 22–26.) Vivos filed its initial Complaint on June 5, 2020, asserting claims for libel, slander, intentional interference with contractual relations, and declaratory judgment on Ortho- Tain’s assertions of Lanham Act violations. (ECF No. 1.) Ortho-Tain filed a Motion to Dismiss in response. (ECF No. 9.) On February 2, 2021, the Court reviewed the Complaint sua sponte and dismissed it without prejudice for failure to comply with Federal Rule of Civil Procedure

8. (ECF No. 39.) The Court denied the Motion to Dismiss as moot and granted Vivos leave to amend its Complaint. (Id.) Vivos filed its AC on February 12, 2021, which is the operative complaint. (ECF No. 40.) Vivos asserts six claims: (1) false advertising in violation of the Lanham Act; (2) violation of the Colorado Consumer Protection Act (“CCPA”), Colo. Rev. Stat. §§ 6- 1-101, et seq.; (3) libel per se; (4) slander per se; (5) intentional interference with contractual relations; and (6) declaratory judgment that Vivos did not violate the Lanham Act as Ortho-Tain allegedly communicated to Benco. (Id. ¶¶ 45–128.) Vivos’s Lanham Act and CCPA claims are based on allegations that in late 2020—after the filing of the initial Complaint—Ortho-Tain began sending advertisements to Vivos’s dentist clients, asserting that Vivos’s brand was inferior to Ortho-Tain’s brand. (Id. ¶¶ 45–78.) Ortho-Tain filed its Motion on February 26, 2021, seeking dismissal of the AC in its entirety pursuant to Rules 12(b)(1) and 12(b)(6). (ECF No. 45.) Vivos responded on March 19, 2021, and Ortho-Tain replied on April 2, 2021. (ECF Nos. 52 & 56.)

II. LEGAL STANDARD A. Rule 12(b)(1) Rule 12(b)(1) empowers a court to dismiss a complaint for “lack of jurisdiction over the subject matter.” Fed. R. Civ. P. 12(b)(1). Dismissal under Rule 12(b)(1) is not a judgment on the merits of a plaintiff’s case. Rather, it calls for a determination that the court lacks authority to adjudicate the matter, attacking the existence of jurisdiction rather than the allegations of the complaint. See Castaneda v. INS, 23 F.3d 1576, 1580 (10th Cir. 1994) (recognizing that federal courts are courts of limited jurisdiction and

may only exercise jurisdiction when specifically authorized to do so). The burden of establishing subject-matter jurisdiction is on the party asserting jurisdiction. Basso v. Utah Power & Light Co., 495 F.2d 906, 909 (10th Cir. 1974). A court lacking jurisdiction “must dismiss the cause at any stage of the proceeding in which it becomes apparent that jurisdiction is lacking.” Id. B. Rule 12(b)(6) Under Federal Rule of Civil Procedure 12(b)(6), a party may move to dismiss a claim in a complaint for “failure to state a claim upon which relief can be granted.” The Rule 12(b)(6) standard requires the Court to “assume the truth of the plaintiff’s well- pleaded factual allegations and view them in the light most favorable to the plaintiff.” Ridge at Red Hawk, 493 F.3d at 1177. In ruling on such a motion, the dispositive inquiry is “whether the complaint contains ‘enough facts to state a claim to relief that is plausible on its face.’” Id. (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). Granting a motion to dismiss “is a harsh remedy which must be cautiously

studied, not only to effectuate the spirit of the liberal rules of pleading but also to protect the interests of justice.” Dias v. City & Cnty. of Denver, 567 F.3d 1169, 1178 (10th Cir. 2009) (internal quotation marks omitted). “Thus, ‘a well-pleaded complaint may proceed even if it strikes a savvy judge that actual proof of those facts is improbable, and that a recovery is very remote and unlikely.’” Id. (quoting Twombly, 550 U.S. at 556). III. ANALYSIS Ortho-Tain seeks dismissal of the AC on several grounds. Namely, Ortho-Tain asserts that Vivos fails to state a claim for relief because it did not obtain leave to amend to assert its Lanham Act and CCPA claims pursuant to Federal Rule of Civil

Procedure 15, that Ortho-Tain’s statements are shielded by an absolute litigation privilege, and that the Court lacks jurisdiction over Vivos’s declaratory judgment claim. (ECF No. 45.) Ortho-Tain further contends that the Court should dismiss the AC for failure to comply with Federal Rules of Civil Procedure 8 and 10. (Id.) A. Rule 15 Amendment Ortho-Tain contends that Vivos impermissibly brought two additional claims—the Lanham Act and CCPA claims—when given leave to amend. (Id. at 3–7.) Due to the additional claims, which are based on certain conduct after the filing of the initial Complaint, Ortho-Tain argues that the AC constitutes an unauthorized supplemental filing.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ridge at Red Hawk, L.L.C. v. Schneider
493 F.3d 1174 (Tenth Circuit, 2007)
Dias v. City and County of Denver
567 F.3d 1169 (Tenth Circuit, 2009)
Cunningham Brothers, Inc. v. Harry Bail
407 F.2d 1165 (Seventh Circuit, 1969)
Amazon.com, Inc. v. National Ass'n of College Stores, Inc.
826 F. Supp. 2d 1242 (W.D. Washington, 2011)
Laffer v. Levinson, Miller, Jacobs & Phillips
34 Cal. App. 4th 117 (California Court of Appeal, 1995)
Basso v. Utah Power & Light Co.
495 F.2d 906 (Tenth Circuit, 1974)

Cite This Page — Counsel Stack

Bluebook (online)
Vivos Therapeutics, Inc. v. Ortho-Tain, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/vivos-therapeutics-inc-v-ortho-tain-inc-cod-2024.